<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542382</url>
  </required_header>
  <id_info>
    <org_study_id>20-30638</org_study_id>
    <nct_id>NCT04542382</nct_id>
  </id_info>
  <brief_title>Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)</brief_title>
  <acronym>BCRPmarker</acronym>
  <official_title>Identification and Validation of Biomarkers for Breast Cancer Resistance Protein</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized, fixed-sequence study. Subjects will undergo a&#xD;
      rosuvastatin phase and eltrombopag and rosuvastatin phase to identify biomarkers for Breast&#xD;
      Cancer Resistance Protein (BCRP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Membrane transporters are critical in the absorption, distribution and elimination of drugs,&#xD;
      and are important target sites for drug-drug interactions (DDIs). During drug development,&#xD;
      clinical studies characterizing transporter-mediated DDIs are frequently required. There has&#xD;
      been enormous interest in identifying and validating serum biomarkers or surrogate probes to&#xD;
      be used in predicting in vivo (clinical) DDIs. These biomarkers could complement in vitro&#xD;
      studies, reducing false positive and false negative predictions, as well as the cost and time&#xD;
      required for clinical development.&#xD;
&#xD;
      In this open-label, non-randomized, fixed-sequence study, subjects will undergo a&#xD;
      rosuvastatin phase and eltrombopag and rosuvastatin phase to identify biomarkers for a&#xD;
      membrane transporter known as Breast Cancer Resistance Protein (BCRP). The primary goal of&#xD;
      this study is to validate and discover BCRP candidate biomarkers in a focused clinical DDI&#xD;
      study with healthy volunteers to determine whether they can serve as clinical biomarkers for&#xD;
      BCRP-mediated DDIs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a single center, an open-label, non-randomized, fixed-sequence study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of pharmacokinetics of co-administration of rosuvastatin and eltrombopag in healthy volunteers.</measure>
    <time_frame>24 and 72 hours</time_frame>
    <description>Mean difference in area under the curve (AUC) between rosuvastatin 10mg + placebo versus rosuvastatin 10mg + eltrombopag 75mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of pharmacokinetics of co-administration of rosuvastatin and eltrombopag in healthy volunteers.</measure>
    <time_frame>24 hour</time_frame>
    <description>Mean difference in Cmax between rosuvastatin 10mg + placebo versus rosuvastatin 10mg + eltrombopag 75mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of BCRP biomarkers of co-administration of rosuvastatin and eltrombopag in healthy volunteers.</measure>
    <time_frame>24 and 72 hours</time_frame>
    <description>Mean difference in BCRP biomarker Cmax between rosuvastatin 10mg + placebo vs rosuvastatin 10mg + eltrombopag 75mg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo and Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with placebo tablet and Rosuvastatin 10mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eltrombopag and Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed with Eltrombopag 75mg tablet and Rosuvastatin 10mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin will be administered as follows:&#xD;
Day 1: single dose of 10 mg Rosuvastatin tablet.</description>
    <arm_group_label>Placebo and Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin (Inhibitor arm)</intervention_name>
    <description>Rosuvastatin will be administered as follows:&#xD;
Day 8: single dose of 10 mg Rosuvastatin tablet.</description>
    <arm_group_label>Eltrombopag and Rosuvastatin</arm_group_label>
    <other_name>Cresto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>Eltrombopag will be administered as follows:&#xD;
Day 8: single dose of 75 mg Eltrombopag tablet.</description>
    <arm_group_label>Eltrombopag and Rosuvastatin</arm_group_label>
    <other_name>Promacta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy as judged by medical examination, medical history and normal biochemical and&#xD;
             hematological measures.&#xD;
&#xD;
          -  Normal urinalysis and renal function&#xD;
&#xD;
          -  Male subjects weighing ≥ 50 kg and female subjects weighing ≥ 45 kg.&#xD;
&#xD;
          -  Understand the nature and purpose of the study and provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are pregnant, breastfeeding, or unwilling to practice non-hormonal forms&#xD;
             of birth control during participation in the study.&#xD;
&#xD;
          -  Self-reported drug allergies to rosuvastatin or eltrombopag&#xD;
&#xD;
          -  Subjects that have smoked cigarettes, have smoked or ingested THC/marijuana or have&#xD;
             used illegal substances (i.e., opiates, cocaine) in the past year.&#xD;
&#xD;
          -  Subjects with any disease affecting or impairing the function of the liver, kidney or&#xD;
             heart.&#xD;
&#xD;
          -  Subjects with any blood or coagulation disorders.&#xD;
&#xD;
          -  Subjects with diabetes mellitus, hyperthyroidism, hypothyroidism, cardiovascular&#xD;
             disease, glaucoma.&#xD;
&#xD;
          -  Subjects with gastrointestinal disease, gastrointestinal disorder, or gastrointestinal&#xD;
             surgery.&#xD;
&#xD;
          -  Subjects with known infection with HIV, Hepatitis B (HBsAg) or Hepatitis C (no&#xD;
             laboratory diagnostics concerning these diseases will be performed within the present&#xD;
             study).&#xD;
&#xD;
          -  Subjects that are taking prescription (i.e., birth control pills), non-prescription&#xD;
             and dietary supplements (i.e., turmeric, quercetin, kaempferol, Gingko biloba) within&#xD;
             seven days of receiving the study dose in each phase of the study.&#xD;
&#xD;
          -  Subjects with a condition, disease, or abnormality that in the opinion of the&#xD;
             Investigator would compromise the safety of the patient or the quality of the data.&#xD;
&#xD;
          -  Female subjects undergoing treatment for infertility or hormone replacement therapy.&#xD;
&#xD;
          -  Subjects with abnormal laboratory results at screening as judged by the investigator&#xD;
             or study physician.&#xD;
&#xD;
          -  Participating in another research study while participating in this research study.&#xD;
&#xD;
          -  Subjects that ingest grapefruit, grapefruit juice or grapefruit extract within seven&#xD;
             days of receiving the study dose in each phase of the study.&#xD;
&#xD;
          -  Non-English speaking.&#xD;
&#xD;
          -  Subject has any signs or symptoms that are consistent with COVID-19. Per current CDC&#xD;
             recommendations this includes subjects with the symptoms cough or shortness of breath&#xD;
             or difficulty breathing, or at least two of the following symptoms: fever, chills,&#xD;
             repeated shaking with chills, muscle pain, headache, sore throat or new loss of&#xD;
             taste/smell. In addition, the subject has any other findings suggestive of COVID-19&#xD;
             risk in the opinion of the investigator.&#xD;
&#xD;
          -  Subject tests positive for severe acute respiratory syndrome coronavirus 2&#xD;
             (SARS-CoV-2) by a molecular diagnostic test (i.e., COVID19 RNA test) performed during&#xD;
             the screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Giacomini, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen M Giacomini, Ph.D.</last_name>
    <phone>41-5476-1936</phone>
    <email>kathy.giacomini@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sook Wah Yee, Ph.D.</last_name>
    <phone>415-514-4363</phone>
    <email>sookwah.yee@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ucsf Ctsi Crc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Deborah Zeitschel, RN, MSN, PhN</last_name>
      <phone>415-218-4927</phone>
      <email>crsprotocolservices@ucsf.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>membrane transporter</keyword>
  <keyword>drug-drug interaction</keyword>
  <keyword>rosuvastatin</keyword>
  <keyword>eltrombopag</keyword>
  <keyword>biomarker</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

